Monopar Therapeutics is a biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. The company currently has three compounds in development: Validive, a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis in patients undergoing radiotherapy for oropharyngeal cancer, Camsirubicin, a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs, and MNPR-101, a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor for the treatment of advanced cancers.
|Employees (est.) (Aug 2019)||4|
|Share Price (Feb 2020)||$10||(-8%)|
Net income (Q3, 2019)
EBIT (Q3, 2019)
Market capitalization (21-Feb-2020)
Closing stock price (21-Feb-2020)
|Company Name||Date||Deal Size|
|Monopar Therapeutics Pty Ltd|
|Monopar Therapeutics, SARL|
When was Monopar Therapeutics founded?
Monopar Therapeutics was founded in 2014.
Who are Monopar Therapeutics key executives?
Monopar Therapeutics's key executives are Chandler D. Robinson, Christopher M. Starr and Kim R. Tsuchimoto.
How many employees does Monopar Therapeutics have?
Monopar Therapeutics has 4 employees.
Who are Monopar Therapeutics competitors?
Competitors of Monopar Therapeutics include Pangaea Oncology, A2 Biotherapeutics and Innate Pharma.
Where is Monopar Therapeutics headquarters?
Monopar Therapeutics headquarters is located at 1000 Skokie Blvd #350Wilmette, Wilmette.
Where are Monopar Therapeutics offices?
Monopar Therapeutics has an office in Wilmette.
How many offices does Monopar Therapeutics have?
Monopar Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies